LISTING OF THE CLAIMS:

1. (Withdrawn – Previously Presented) A method of producing a discrete film dosage, comprising:

a) forming a non-gelatin polymeric film without active ingredients incorporated therein;

b) applying a polar liquid carrier to one or more surfaces of the film, the polar liquid carrier incorporating at least one active ingredient; and

c) allowing the applied polar liquid carrier to associate and cure with the film, to result in the complete absorption of the at least one active ingredient within the film forming a polymer film product.

2. (Withdrawn) A method according to claim 1, wherein the non-gelatin film produced comprises one or more layers which associate with one another to a lesser or greater degree to form a partially or wholly polymerically homogeneous film.

3. (Withdrawn) A method according to claim 1, wherein the polymeric mass of the film or films is increased marginally or substantially after steps b) or c).

4. (Cancelled)

5. (Withdrawn) A method according to claim 1 whereby one or more polymeric substances are also deposited on the film surface.

6. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient in the polar liquid carrier is transported into the film during step c) of claim 1.

7. (Withdrawn – Previously Presented) A method according to claim 2 wherein the at least one active ingredient is selectively transported.

8. (Withdrawn) A method according to claim 1, wherein the non-gelatin film comprises a cellulose ether film.

9. (Withdrawn – Previously Presented) A method according to claim 1, wherein the non-gelatin film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),

hydroxy propyl cellulose (HPC),

hydroxy ethyl methyl cellulose (HEMC),

hydroxy ethyl cellulose (HEC),

methyl cellulose (MC),

carboxy methylcellulose (CMC),

ethyl cellulose (EC),

sodium carboxy methylcellulose

and salts and derivatives of all aforesaid.

10. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier comprises a same or similar polymeric material as to which forms the non-gelatin film.

11. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the material which forms the non-gelatin film.

12. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient is transported from the polar liquid carrier into the film.

13. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient has a higher affinity for the polar liquid carrier than the film.

14. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient has a higher affinity for the film than the polar liquid carrier.

15. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier incorporates 2 or more active ingredients having the same or differing affinities for the film and the polar liquid carrier.

16. (Previously Presented) A discrete film dosage to be taken orally, internally, or epidermally produced by the method of:

a) forming a non-gelatin polymeric film without active ingredients incorporated therein;

b) applying a polar liquid carrier to one or more surfaces of the film, the polar liquid carrier incorporating at least one active ingredient; and

c) allowing the applied polar liquid carrier to associate and cure with the film, to result in the complete absorption of the at least one active ingredient within the film forming a polymer film product.

17. (Cancelled)

18. (Previously Presented) A discrete film dosage according to claim 16, wherein the at least one active ingredient has a concentration gradient associated with one or more bands or patterns within the film.

19. (Previously Presented) A discrete film dosage according to claim 16, wherein the at least one active ingredient continues to move or be transported within the film after the polar liquid carrier is allowed to at least partially cure and associate with the film.

20. (Previously Presented) A discrete film dosage according to claim 16, wherein one or more layers of the film associate with one another to form a level of polymeric homogeneity.

21. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is coiled.

22. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is folded in a zig-zag formation.

23. (Previously Presented) A pharmaceutical dosage form comprising multi-layers of film formed from the discrete film dosage according to claim 16.

24. (Previously Presented) A pharmaceutical dosage form according to claim 23, wherein the films are laid together before any polar liquid carrier applied has cured or dried.

25. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is packaged to form a dose unit.

26. (Previously Presented) A discrete film dosage according to claim 16, wherein the polar liquid carrier is applied to the film to form a pattern.

27. (Cancelled)

28. (Previously Presented) A pharmaceutical dosage form derived from a discrete film dosage according to claim 16.

29. (Withdrawn – Previously Presented) Use of a discrete film dosage according to claim 16, wherein the polymer film product is placed on the tongue of a human or animal and the

at least one active ingredient is released in a convenient manner as the polymer film product disintegrates.

30. (Previously Presented) A tablet, powder slug or capsule made from or coated, enrobed or encapsulated with a discrete film dosage according to claim 16.

31. (Previously Presented) A tablet or monolith made from multiple layers of a discrete film dosage according to claim 16.

32. (Previously Presented) A tablet or monolith according to claim 31, wherein said tablet or monolith comprises three to forty layers.

33. (Previously Presented) A tablet or monolith according to claim 31, wherein said tablet or monolith comprises 8 to 25 layers.

34. (Previously Presented) A tablet of monolith according to claim 31, wherein the tablet or monolith comprises 10 to 20 layers.

35. (Previously Presented) A multicellular dosage form made from a discrete film dosage according to claim 16.

36. (Withdrawn – Previously Presented) A method according to claim 10, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the

material which forms the non-gelatin film, and wherein 2 or more active ingredients have the same or differing affinities for the film and liquid.

37. (Previously Presented) A discrete film dosage according to claim 18, wherein the polymer film product is coiled.

38. (Previously Presented) A discrete film dosage according to claim 19, wherein the polymer film product is coiled.

39. (Previously Presented) A discrete film dosage according to claim 20, wherein the polymer film product is coiled.

40. (Previously Presented) A non-gelatin polymeric film wherein said film comprises two or more bands, at least one active ingredient being dispersed within a particular band, said film being a single film with structural homogeneity between said bands.

41. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymeric film is initially un-plasticized or partially plasticized, and the applied polar liquid carrier confers a plasticizing effect to the film.

42. (Previously Presented) A discrete film dosage according to claim 16, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the non-gelatin polymeric film.

43. (Previously Presented) A discrete film dosage according to claim 16, wherein the polar liquid carrier is cured at room temperature.

44. (Previously Presented) A discrete film dosage according to claim 16, wherein the polar liquid carrier is cured through application of heat to a temperature below the boiling point of the polar liquid carrier.

45. (Previously Presented) A discrete film dosage according to claim 16, wherein the mass of the film is increased after steps b) and c).

46. (Previously Presented) A discrete film dosage according to claim 16, wherein the non-gelatin polymeric film comprises a cellulose ether film.

47. (Previously Presented) A discrete film dosage according to claim 16, wherein the non-gelatin polymeric film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),

hydroxy propyl cellulose (HPC),

hydroxy ethyl methyl cellulose (HEMC),

hydroxy ethyl cellulose (HEC),

methyl cellulose (MC),

carboxy methylcellulose (CMC),

ethyl cellulose (EC),

sodium carboxy methylcellulose,

and salts and derivatives of all aforesaid.

48. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is edible.

49. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is muco-adhesive.

50. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is a medical device.

51. (Previously Presented) A discrete film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier has at least one of a therapeutic effect, an organoleptic effect, a cosmetic effect, and a pharmaceutical effect.

52. (Previously Presented) A discrete film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier is a pharmaceutical compound.

53. (Previously Presented) A pharmaceutical dosage form derived from a discrete film dosage according to claim 16.

54. (Previously Presented) A discrete film dosage according to claim 16, wherein the at least one active ingredient has a concentration gradient associated with one or more patterns within the polymer film product.

55. (Previously Presented) A discrete film dosage according to claim 16, wherein the polymer film product is can be applied mucosally, orally, or topically.